129 related articles for article (PubMed ID: 30852481)
1. Clinical effect of the extract of TCM Fructus akebiae combined with ursodeoxycholic acid on nonalcoholic fatty liver disease.
Hongguang J; Xingjie H; Mingliang J; Yun L; Tongjian L; Jingmo Y; Liang L; Lifang Z
Pak J Pharm Sci; 2019 Jan; 32(1(Special)):433-437. PubMed ID: 30852481
[TBL] [Abstract][Full Text] [Related]
2. Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice.
Kim JK; Lee KS; Lee DK; Lee SY; Chang HY; Choi J; Lee JI
Exp Mol Med; 2014 Dec; 46(12):e127. PubMed ID: 25523099
[TBL] [Abstract][Full Text] [Related]
3. An open-label randomized control study to compare the efficacy of vitamin e versus ursodeoxycholic acid in nondiabetic and noncirrhotic Indian NAFLD patients.
Parikh P; Ingle M; Patel J; Bhate P; Pandey V; Sawant P
Saudi J Gastroenterol; 2016; 22(3):192-7. PubMed ID: 27184636
[TBL] [Abstract][Full Text] [Related]
4. Ursodeoxycholic acid ameliorates hepatic lipid metabolism in LO2 cells by regulating the AKT/mTOR/SREBP-1 signaling pathway.
Hu J; Hong W; Yao KN; Zhu XH; Chen ZY; Ye L
World J Gastroenterol; 2019 Mar; 25(12):1492-1501. PubMed ID: 30948912
[TBL] [Abstract][Full Text] [Related]
5. Is vitamin e or ursodeoxycholic acid a valid treatment option for nonalcoholic fatty liver disease in 2016?
Beaton MD; Al-Judaibi B
Saudi J Gastroenterol; 2016; 22(3):169-70. PubMed ID: 27184632
[No Abstract] [Full Text] [Related]
6. Non-alcoholic fatty liver disease as a cause and consequence of cardio-metabolic complications. Role of the ursodeoxicholic acid in the pharmacotherapy.
Maevskaya MV; Ivashkin VT; Ivashkin KV; Lunkov VD; Liusina EO; Zozula VN; Leshchenko VI
Ter Arkh; 2019 Mar; 91(2):109-117. PubMed ID: 31094181
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effects of curcumin and ursodexycholic acid on non-alcoholic fatty liver disease.
Gheibi S; Gouvarchin Ghaleh HE; Motlagh BM; Azarbayjani AF; Zarei L
Biomed Pharmacother; 2019 Jul; 115():108938. PubMed ID: 31071511
[TBL] [Abstract][Full Text] [Related]
8. [Comparison on the efficacy and safety of biphenyl dimethyl dicarboxylate and ursodeoxycholic acid in patients with abnormal alanine aminotransferase: multicenter, double-blinded, randomized, active-controlled clinical trial].
Lee SH; Cheon GJ; Kim HS; Kim YD; Kim SG; Kim YS; Jeong SW; Jang JY; Kim BS
Korean J Gastroenterol; 2014 Jul; 64(1):31-9. PubMed ID: 25073669
[TBL] [Abstract][Full Text] [Related]
9. Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment.
Ersöz G; Günşar F; Karasu Z; Akay S; Batur Y; Akarca US
Turk J Gastroenterol; 2005 Sep; 16(3):124-8. PubMed ID: 16245220
[TBL] [Abstract][Full Text] [Related]
10. A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid.
Santos VN; Lanzoni VP; Szejnfeld J; Shigueoka D; Parise ER
Braz J Med Biol Res; 2003 Jun; 36(6):723-9. PubMed ID: 12792701
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of non-alcoholic steatohepatitis (NASH). A comparative study of ursodeoxycholic acid and alpha-tocopherol. A preliminary report].
Bernal-Reyes R; Escudero RB
Rev Gastroenterol Mex; 2002; 67(2):70-5. PubMed ID: 12214337
[TBL] [Abstract][Full Text] [Related]
12. [UDCA in the treatment of nonalcoholic fatty liver disease].
Grigor'eva IN
Eksp Klin Gastroenterol; 2011; (11):79-85. PubMed ID: 22629725
[TBL] [Abstract][Full Text] [Related]
13. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
Günsar F; Akarca US; Ersöz G; Karasu Z; Yüce G; Batur Y
Hepatogastroenterology; 2002; 49(47):1195-200. PubMed ID: 12239904
[TBL] [Abstract][Full Text] [Related]
14. [Efficiency of ursodeoxycholic acid therapy in non-alcoholic fatty liver disease associated with metabolic syndrome].
Avalueva EB; Tkachenko EI; Skazyvaeva EV; Ivanov SV; Orishak EA; Lapinskiĭ IV
Eksp Klin Gastroenterol; 2013; (11):26-30. PubMed ID: 24933975
[TBL] [Abstract][Full Text] [Related]
15. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.
Tarao K; Fujiyama S; Ohkawa S; Miyakawa K; Tamai S; Hirokawa S; Masaki T; Tanaka K
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):164-9. PubMed ID: 15668491
[TBL] [Abstract][Full Text] [Related]
16. A randomized controlled trial comparing the effects of Vitamin E, Ursodeoxycholic acid and Pentoxifylline on Egyptian non-alcoholic steatohepatitis patients.
Fouda A; Abdelaziz AE; Hussien M; Ali AA; Abdelkawy KS; Elbarbry F
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7449-7459. PubMed ID: 34919247
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of ursodeoxycholic acid composite on fatigued patients with elevated liver function and/or fatty liver: a multi-centre, randomised, double-blinded, placebo-controlled trial.
Oh B; Choi WS; Park SB; Cho B; Yang YJ; Lee ES; Lee JH
Int J Clin Pract; 2016 Apr; 70(4):302-11. PubMed ID: 26997458
[TBL] [Abstract][Full Text] [Related]
18. Effects of ursodeoxycholic acid therapy on carotid intima media thickness, apolipoprotein A1, apolipoprotein B, and apolipoprotein B/A1 ratio in nonalcoholic steatohepatitis.
Ozel Coskun BD; Yucesoy M; Gursoy S; Baskol M; Yurci A; Yagbasan A; Doğan S; Baskol G
Eur J Gastroenterol Hepatol; 2015 Feb; 27(2):142-9. PubMed ID: 25533429
[TBL] [Abstract][Full Text] [Related]
19. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review.
Xiang Z; Chen YP; Ma KF; Ye YF; Zheng L; Yang YD; Li YM; Jin X
BMC Gastroenterol; 2013 Sep; 13():140. PubMed ID: 24053454
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of primary biliary cirrhosis with ursodeoxycholic acid].
Nikolovska D; Vasilev P; Mikhova A
Vutr Boles; 2000; 32(1):25-7. PubMed ID: 11195193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
